Frequent osteopontin expression is typical of, but not specific for malignant pleural mesothelioma, whereas it appears to select pulmonary adenocarcinoma cases with p65 and MMP-9 expression, suggesting a link with EGFR signalling pathways.

RelA,was observed as increased expression in non-small cell lung cancer tissues

AhR, without exposure to a ligand, associates with RelA, which then positively modulates NFkappaB activity and then upregulates IL-6 expression in human lung cells; a new mechanism for lung tumorigenesis

Myeloid RelA/p65 is necessary to link smoke-induced inflammation with lung cancer growth.

RGC32 promotes cell migration and invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway.

In non-small cell lung cancer, tumor area RelA expression was correlated with, and an independent predictor of the intensity of inflammatory infiltration.

Inactivation of M2 AChR/NF-kappaB signaling axis reverses epithelial-mesenchymal transition and suppresses migration and invasion in non-small cell lung cancer.

Findings indicate that CARMA3 may suppress the activation of the P38 MAPK signaling pathway to regulate invasion, migration and apoptosis of lung cancer cells by activating NF-small ka, CyrillicB (P65) in the nucleus.

The pathological tissues of Xuanwei lung-cancer patients express high level of NF-kappaB-p65, and iNOS.

S-allylmercaptocysteine inhibits lung cancerogenesis by suppression of NF-kappaB pathways

TCF-4 is a co-activator of NF-kappaB p65 that promotes MMP-15 transcription and potentiate the migration activity of the lung cancer cells

NFKB1 -94insertion/deletion ATTG polymorphism associated with decreased risks for lung cancer, nasopharyngeal carcinoma, prostate cancer, ovarian cancer, and oral squamous cell carcinoma.

p65 O-GlcNAcylation promotes lung metastasis of cervical cancer cells by activating CXCR4 expression.

Co-expression of p65 and phosphorylated p105 but not of either p65 or phosphorylated p105 alone was associated with a poor prognosis in surgically resectable non-small cell lung cancer patients.

the non-small cell lung cancer (NSCLC) cells within miR-7 + RELA group were observed with superior proliferative, migratory and invasive capabilities than those within miR-7 group (P < .05), and RELA expression was also significantly modified by both ciRS-7 and miR-7 (P < .05). In conclusion, the ciRS-7/miR-7/NF-kB axis could exert pronounced impacts on the proliferation, migration, invasion and apoptosis of NSCLC cells.

Hesperetin reverses Pglycoproteinmediated cisplatin resistance in DDPresistant human lung cancer cells via modulation of the nuclear factorkappaB signaling pathway.

PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.

Pentraxin 3 acts as a functional effector of Akt/NF-kappaB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.